Trial Profile
A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Apr 2022
Price :
$35
*
At a glance
- Drugs Insulin degludec/liraglutide (Primary) ; Insulin aspart; Insulin glargine
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms DUAL VII
- Sponsors Novo Nordisk
- 08 Nov 2019 Results of post hoc analysis of two trials (DUAL V and DUAL VII) were published in the Diabetic Medicinepublished in the Diabetic Medicine
- 23 Jan 2019 According to a Novo Nordisk media release, Xultophy was approved by Health Canada in April 2018 based on data from the DUAL clinical development program.
- 05 Oct 2018 Results of post hoc analysis evaluating the treatment complexity of IDegLira vs. BB in terms of number of injections and dose adjustments presented at the 54th Annual Meeting of the European Association for the Study of Diabetes